OncoMatch/Clinical Trials/NCT06152731

HRD Tests for Ovarian cancER

Is NCT06152731 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for ovarian cancer.

Phase 2RecruitingCentre Francois BaclesseNCT06152731Data as of May 2026

The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy. To determine HRD status, 2 separate tests will be performed in the study: 1. Giscar assay : developed by the sponsor 2. myChoice assay If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Disease stage

Required: Stage III, IV

Grade: high grade

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify